The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the market in the coming years.
The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Epigenetics refers to the covalent modification of DNA, RNA, or protein that results in changes to the function and/or regulation of these molecules, without altering their primary sequences. These modifications can occur naturally, or can be influenced, by several factors including age, environment, disease state, and changes in lifestyle.
Global Epigenetics Market Segmented by:
1. Product
2. Application
3. Technology
4. End User
5. Region
Product:
1. Enzymes
2. Instruments and Consumables
3. Kits
4. Reagents
5. Bioinformatics Tools
Application:
1. Oncology
2. Metabolic Diseases
3. Developmental Biology
4. Immunology
5. Cardiovascular Disease
By Technology:
1. DNA Methylation
2. Histone Modifications
By End User:
1. Academic and Research Institutes
2. Pharmaceutical and Biotechnology Companies
3. Contract Research Organizations (CROs)
By Region:
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East and Africa
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
The epigenetics market in Asia-Pacific region is expected to witness the highest CAGR during the forecast period of 2017 to 2022. The growth of this segment can be attributed to the increasing R&D spending, increasing government initiatives, and rising focus on key market players in the region. Emerging markets such as Brazil, China, and India offer significant growth potential to market players. This can primarily be attributed to the diversified healthcare market in this region, growing incidence of infectious and chronic disorders, and increasing R&D initiatives targeted at the development of innovative genomic techniques.
Key Players:
The epigenetics market is fragmented with a large number of players offering a variety of products. The prominent players in the global market are Illumina (US), Thermo Fisher Scientific (US), Merck Millipore (US), Abcam (UK), Active Motif (US), Bio-Rad Laboratories (US), New England Biolabs (US), Agilent (US), QIAGEN (Netherlands), Zymo Research (US), PerkinElmer (US), and Diagenode (Belgium).
Expanding Application Areas of Epigenetics in Non Oncology Diseases.
The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025.
Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases.
Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.The identification of severity among patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain.
High-end demand for latest technologies in healthcare sector and collective research and development (R) activities in the area of genetics is anticipated to foster industry growth as well.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/epigenetics-market-size/request-sampleSeveral diagnostic and testing organization have launched innovative products including antibodies specific for identification of modifications and advanced kits for simple and efficient detection of biomarkers.
Introduction of pipeline drugs and rising approval rate from local and international authorities is estimated to augment epigenetics industry growth over the coming years.Rising approval rate for therapeutic drugs and epigenetics services is the key industry trend over the past few years.
For example, Eli Lilly and Co., global pharmaceutical company, has unveiled its product line of advanced therapeutic drugs Ramucirumab (Cyramza), which is recently approved by FDA.
The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025.
Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases.
Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.The identification of severity among patients suffering from chronic diseases and successful execution of disease management are other major factors driving the growth of the genetic testing services domain.
High-end demand for latest technologies in healthcare sector and collective research and development (R) activities in the area of genetics is anticipated to foster industry growth as well.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/epigenetics-market-size/request-sampleSeveral diagnostic and testing organization have launched innovative products including antibodies specific for identification of modifications and advanced kits for simple and efficient detection of biomarkers.
Introduction of pipeline drugs and rising approval rate from local and international authorities is estimated to augment epigenetics industry growth over the coming years.Rising approval rate for therapeutic drugs and epigenetics services is the key industry trend over the past few years.
For example, Eli Lilly and Co., global pharmaceutical company, has unveiled its product line of advanced therapeutic drugs Ramucirumab (Cyramza), which is recently approved by FDA.